Kcs Wealth Advisory Gilead Sciences, Inc. Transaction History

Kcs Wealth Advisory

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 16, 2020	SELL	$72.34 - $84.0 $193,075 - $224,196	-2,669 Closed	0 $0
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $167,159 - $214,107	2,669 New	2,669 $200,000
Q4 2019 Jan 15, 2020	SELL	$61.62 - $67.78 $190,898 - $209,982	-3,098 Closed	0 $0
Q3 2019 Oct 29, 2019	SELL	$62.51 - $69.0 $51,945 - $57,339	-831 Reduced 21.15%	3,098 $196,000
Q2 2019 Jul 29, 2019	SELL	$61.87 - $69.38 $1,608 - $1,803	-26 Reduced 0.66%	3,929 $265,000
Q1 2019 Apr 29, 2019	BUY	$62.53 - $70.05 $15,632 - $17,512	250 Added 6.75%	3,955 $257,000
Q4 2018 Jan 17, 2019	BUY	$60.54 - $79.0 $224,300 - $292,695	3,705 New	3,705 $232,000
Q3 2018 Nov 06, 2018	SELL	$71.28 - $78.92 $204,644 - $226,579	-2,871 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$64.88 - $75.68 $13,949 - $16,271	-215 Reduced 6.97%	2,871 $203,000
Q1 2018 May 04, 2018	BUY	$72.84 - $88.8 $224,784 - $274,036	3,086 New	3,086 $233,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Kcs Wealth Advisory, based on Form 13F filings with the SEC.

Stay updated on Kcs Wealth Advisory with notifications on news.